DALLAS, March 12, 2010 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring NexMed Inc. (Nasdaq:NEXM). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The full report is available at: http://www.beaconequity.com/i/NEXM
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
NexMed (NEXM) is the largest specialty CRO based in San Diego, Calif., and is one of the industry's most experienced CROs for in vitro and in vivo pharmacology services and research models. The Company's goal is to generate revenues from the growth of its Discovery Pre-clinical CRO business, while aggressively seeking to monetize its proprietary NexACT drug delivery technology throughout licensing agreements with pharmaceutical and biotechnology companies, worldwide. The Company is actively pursuing partnering opportunities for its NexACT-based treatments for onychomycosis, psoriasis, sexual dysfunction and cancer.
In the report, the analyst notes:
"The market for drug therapies to treat male sexual disorders is approximately $4.3 billion, with sales expected to grow at a compounded rate of 4.9% per year until 2012, according to life sciences research firm BioPortfolio Ltd. Some form of erectile dysfunction (ED) affects a little more than half of the male population between the age of 40 and 70 years, according to the Massachusetts Male Aging study (MMAS).
"The Company's drug discovery and development arm, NexMed USA, has an extensive product pipeline ranging from early stage products to NDA stage products in the areas of dermatology, sexual dysfunction, pain, and potentially moving into oncology."
To read the entire report visit: http://www.beaconequity.com/i/NEXM
See what investors are saying about these stocks at penny stock forum.
BeaconEquity.com is one of the industry's largest small-cap report providers striving to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.